Pregnancy represents a dynamic period with physical and physiological changes in both the mother and her developing fetus. The dramatic 2-3 fold increase in the active hormone 1,25(OH) 2 D concentrations during the early weeks of pregnancy despite minimal increased calcium demands during that time of gestation and which are sustained throughout pregnancy in both the mother and fetus suggests an immunomodulatory role in preventing fetal rejection by the mother. While there have been numerous observational studies that support the premise of vitamin D's role in maintaining maternal and fetal well-being, until recently, there have been few randomized clinical trials with vitamin D supplementation. One has to exhibit caution, however, even with RCTs, whose results can be problematic when analyzed on an intent-to-treat basis and when there is high non-adherence to protocol (as if often the case), thereby diluting the potential good or harm of a given treatment at higher doses. As such, a biomarker of a drug or in this case "vitamin" or pre-prohormone is better served. For these reasons, the effect of vitamin D therapies using the biomarker circulating 25(OH)D is a far better indicator of true "effect." When pregnancy outcomes are analyzed using the biomarker 25(OH)D instead of treatment dose, there are notable differences in maternal and fetal outcomes across diverse racial/ethnic groups, with improved health in those women who attain a circulating 25(OH)D concentration of at least 100 nmol · L − 1 (40 ng · mL − 1 ). Because an important issue is the timing or initiation of vitamin D treatment/supplementation, and given the potential effect of vitamin D on placental gene expression and its effects on inflammation within the placenta, it appears crucial to start vitamin D treatment before placentation (and trophoblast invasion); however, this question remains unanswered. Additional work is needed to decipher the vitamin D requirements of pregnant women and the optimal timing of supplementation, taking into account a variety of lifestyles, body types, baseline vitamin D status, and maternal and fetal vitamin D receptor (VDR) and vitamin D binding protein (VDBP) genotypes. Determining the role of vitamin D in nonclassical, immune pathways continues to be a challenge that once answered will substantiate recommendations and public health policies.
INTRODUCTION
Pregnancy represents a time of immense change, which includes changes in physical proportions, physiology and responsibility. Arguably, nothing during these times changes more than the requirement and metabolism of vitamin D. Do the current recommendations for the requirements of vitamin D during these critical time periods reflect emerging data? Sadly, no. The minimal recommendations by the Institute of Medicine 1 of 400-600 IU vitamin D During these dramatic times of physiological change, the roles of vitamin D in the pregnant versus, for example, the lactating woman are quite different. In the pregnant women, we believe the primary role of vitamin D to be an immunomodulatory-rather than a calcium-regulating factor, although, it would also retain that function. Further, vitamin D inadequacy in early life is clearly an instance of the "Barker Hypothesis". 4 This theory states that certain adult-onset diseases might have their roots in nutritional insults sustained in the perinatal period (either in utero or in the early months of infancy or both). Clearly, conditions associated with vitamin D deficiency such as asthma, multiple sclerosis (MS) and other neurological disorders would qualify. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] If one is reading this review for historical facts presented during the past 50 years of vitamin D recommendations during pregnancy, we suggest you read other recent publications for history in this area. [16] [17] However, if the reader is interested in gaining new insight into the vitamin D requirements and function during pregnancy supported by recent data, we suggest you read on. Also, as a word of caution, with regard to randomized controlled trials (RCT's) for vitamin D, we discuss the criteria that must be asserted when applied to nutrient research, without which they are largely doomed to fail. 18 The reasons for this are many and specific cases of this failure will be presented in this text.
VITAMIN D NOMENCLATURE AND METABOLISM
There are two forms of vitamin D: D 2 and D 3 . Vitamin D 2 , or ergocalciferol, is made by plants, and fungi such as mushrooms; and vitamin D 3 , or cholecalciferol, is made by animals, including humans, and both are often referred to as the "parent compound". For the remainder of the review, vitamin D will be used as a reference to both compounds unless otherwise noted. Vitamin D 3 is formed in the skin upon exposure to ultraviolet light exposure; 19 vitamin D 3 is also acquired through dietary supplementation along with vitamin D 2 with the amount of this supplementation generally the source of lingering controversy. 1, [20] [21] [22] Since we are largely a society that avoids sun exposure, the role of dietary supplementation becomes extremely important. Once in the circulation, vitamin D is then converted into 25-hydroxyvitamin D [25 (OH) D], which is the major circulating form of the vitamin. This conversion of vitamin D to 25 (OH) D is achieved primarily in the liver but can also be achieved in a variety of tissues in an autocrine/paracrine fashion. 23 Finally, 25(OH)D is converted into the hormonal form of the vitamin-1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D]-in the kidney for endocrine function and other tissues for autocrine/paracrine function. 23 This concept is explained in detail elsewhere. 23 
VITAMIN D METABOLISM DURING PREGNANCY WHEN COMPARED WITH THE NON-PREGNANT STATE
A striking difference exists in vitamin D metabolism during pregnancy and fetal development compared with nonpregnancy and non-fetal states, a point that has been known for at least the past three decades but which has received little attention until recently. [24] [25] [26] [27] [28] The conversion of vitamin D to 25(OH)D appears unchanged during pregnancy, following first-and-zero-order enzyme kinetics. 29 By contrast, the conversion of 25 (OH) The rise in circulating 1,25(OH) 2 D levels in the mother/ fetus is a remarkable observation. Early-on, the thought was that this increase was to ensure adequate delivery of calcium to the maternal skeleton preservation and fetal skeletal development. Calcium homeostasis, however, is not linked with this increase in 1,25(OH) 2 D, because at 12 weeks of gestation there is no increase in calcium demand by either the mother or fetus. In contrast, this increased concentration of 1,25(OH) 2 D sustained during pregnancy is not sustained during lactation when maternal calcium demand is at least as high as during pregnancy. 34 Thus, in the mother and fetus during pregnancy, the rise in 1,25(OH) 2 D is dependent on substrate availability-in this case-25(OH)D, and is largely independent of calcium homeostasis. 30 The control of circulating concentrations of vitamin D, 25 (OH)D, and 1,25(OH) 2 D is a complex matter, affected by many disease states such as malabsorption syndromes, aberrant vitamin D metabolism as in sarcoidosis and/or disruptions in the calcium homeostatic system and so on. 35 Although these are all important, they are beyond the scope of this short review and are not considered further; consideration is given only to what happens to these compounds under normal conditions when vitamin D is obtained through the diet or UV-light induction and how they enter normal cells.
In humans, vitamin D 3 is naturally obtained when sunlight in the UVB range strikes the skin and causes 7-dehydrocholesterol to be converted, following a membrane-enhanced thermal dependent isomerization reaction, into vitamin D 3 , which then diffuses into the circulation through the capillary bed. 36 Vitamin D also is obtained orally through the diet as either vitamin D 2 or D 3 .
As far as can be determined from the literature, this absorption process is primarily diffusion-based, is dependent on bile acid solubilization, and is not saturable. [37] [38] [39] When vitamin D 3 enters the circulation after UV exposure, it is primarily associated with vitamin D-binding protein (VDBP). In contrast, after intestinal absorption, it is coupled with both VDBP and lipoproteins. 40 Vitamin D from either route is delivered primarily to the liver, where 25(OH)D is produced, becomes associated with VDBP, and is discharged into the circulation. 41 Not only circulated to the liver, vitamin D also is circulated to all tissues in the body; many of which are now known to contain both the activating hydroxylase and the vitamin D 25-hydroxylase that converts vitamin D into 25(OH)D, thus achieving autocrine production of 25(OH)D in those tissues [42] [43] [44] [45] [46] ( Figure 1 ). We believe this to be an underappreciated and very important event that has not yet been adequately considered or investigated.
On reaching the circulation, the primary determinant of how long a vitamin D metabolite will stay in circulation is its affinity for VDBP. 47 [50] [51] [52] These dissociation constants also dictate the "free" concentration of compound that is available to enter into cells to be metabolized or to modulate cell activity ( Figure 1 ). In the case of these three compounds, the "free" circulating concentrations are greater for 1,25(OH) 2 D than for intact vitamin D, which in turn is larger than that of 25(OH)D, matching their relative circulating half-lives. Besides cellular diffusion of free compound, there exists another important tissue-the transport mechanism for these steroids-the megalin-cubilin endocytotic system. 53 This system is key in the delivery of 25(OH)D to the 25-hydroxyvitamin D-1-α-hydroxylase in the kidney, 54 which also exists in the parathyroid glands, making its important role in the endocrine function of vitamin D self-evident. 55 The megalin-cubilin system also functions in the placenta 56 and brain, 57 As shown in Figure 1 , this observation is taken one step further. Besides being the most potent stabilizer, vitamin D 3 would also be the metabolite most accessible to the cell membrane to impart that function. That is because circulating 25(OH)D 3 is almost totally bound to the VDBP and its "free" concentration so miniscule that there simply is not enough to matter. 1,25(OH) 2 D 3 , while existing in a high circulating "free" form, simply circulates at a level of insignificance for this function. While vitamin D 3 following its synthesis in the skin would have a slightly longer half-life as opposed to oral dose vitamin D, these differences are minor compared to the half-life of 25(OH)D, which is weeks compared to days. 40 Given the perceived risks of UV-light exposure, dosing currently in vitamin D studies is by oral supplementation rather than UV-light therapy. Vitamin D 3 , then, if given at physiological doses of 4 000
greater, would circulate in the "free" form at significant levels and be available to membrane insertion and subsequent endothelial stabilization that is likely to have profound effects on several disease processes. This is truly a new frontier in vitamin D mode of action.
OBSTETRICAL "PARANOIA" WITH REGARD TO VITAMIN D ADMINISTRATION DURING PREGNANCY
We refer to this type of thinking as "medical lore"; however, in this particular case because it carries forth into current medical care, we view it as dangerous. It happens when medical students are taught something that is based on obsolete data that have carried through to the present. This is absolutely the case with the use of vitamin D during pregnancy. Why is this? Because of the British experience with idiopathic infantile hypercalcemia attributed to hypervitaminosis D, a terrible, inaccurate association occurred that had a profound effect on the potential of vitamin D supplementation, not only during infancy but also during pregnancy. In 1963, Black and Bonham-Carter 70 recognized that elfin facies observed in patients with severe idiopathic infantile hypercalcemia resembled the peculiar facies observed in patients with supravalvular aortic stenosis (SAS) syndrome. Shortly thereafter, Garcia et al. 71 documented the occurrence of idiopathic hypercalcemia in an infant with SAS who also had peripheral pulmonary stenosis, mental retardation, elfin facies and an elevated blood concentration of vitamin D. This is an interesting observation because, in 1964, when the article was published, there were no quantitative means of assessing circulating concentrations of vitamin D. In fact, at that time, it was not even proven that vitamin D was further metabolized within the body. By 1967, vitamin D was viewed by the medical community as the cause of SAS syndrome. [72] [73] As a result of the theory that maternal vitamin D supplementation during pregnancy caused SAS syndrome, 74 animal models were developed to show that toxic excesses of vitamin D during pregnancy would result in SAS. [75] [76] In these earlier cases, 70 vitamin D had nothing to do with the etiology of SAS. What was described as vitamin D-induced SAS syndrome is now known as Williams Syndrome. [77] [78] Unfortunately, vitamin D intake during pregnancy is still associated with SAS. Williams Syndrome is a rare developmental disorder and severe genetic affliction related to elastin gene disruption 77 that is caused by 26-28 elastin and contiguous deleted genes on chromosome 7 g 11.23. This syndrome is characterized by multiorgan involvement (including SAS), dysmorphic facial features, and a distinctive cognitive profile. 78 brain function, [13] [14] [15] and respiratory function. 6 More recent studies have pointed to maternal vitamin D deficiency as a risk factor for abnormal fetal growth patterns, adverse birth outcomes, and reproductive failure. [90] [91] [92] [93] [94] Also, a recent meta-analysis of observational studies has confirmed the fact that maternal vitamin D deficiency increases the risk of preterm birth. 95 Although public policy cannot be set for supplementation practices based on observational studies, this information is invaluable at pointing research in the direction that could yield public policy changes in vitamin D consumption. These next steps are interventional studies or better yet, randomized clinical trials (RCTs). One has to exhibit caution, however, even with RCTs, whose results can be problematic when analyzed on an intent-to-treat basis and when there is high nonadherence to protocol (as is often the case), thereby diluting the potential good or harm of a given treatment at higher doses. As such, a biomarker of a drug or in this case "vitamin" or preprohormone is better served. For these reasons, analyses of effect of vitamin D therapies using 25(OH)D concentration is a far better indicator of true "effect".
RANDOMIZED CONTROLLED TRIALS INVESTIGATING VITAMIN D SUPPLEMENTATION DURING PREGNANCY
Enthusiasm for evidence-based medicine (EBM) has resulted in the extension of its methods to the evaluation of nutrient effects. Heaney 18 has pointed out EMB, as applied in the evaluation of drugs, is poorly suited to the study of nutrients. In a drug trial, the placebo group will be totally devoid of the compound in question; not so for a nutrient like vitamin D. To perform a true RCT for vitamin D one would have to make sure all subjects were vitamin D-deficient at the study onset. For the duration of the study all subjects would have to remain indoors to avoid any sun exposure. Then and only then could a true RCT be performed for any given function of vitamin D.
Of course, what we have suggested here is unethical and is never going to take place. How then does one proceed? Heaney 18 has provided excellent guidance in this regard.
Dr. Heaney proposes five rules for individual clinical studies of nutrient effects. These rules are as follows: (1) basal nutrient status must be measured, used as an inclusion criterion for entry into the study, and recorded in the report of the trial; (2) the intervention must be large enough to change nutrient status and must be quantified by suitable analysis; (3) the change in nutrient status produced in those enrolled in the report of the trial must be measured and reported; (4) the hypothesis to be tested must be that a change in nutrient status produces the sought-for-effect; and (5) co-nutrient status must be optimized in order to ensure that the nutrient is the only nutrition-related, limiting factor in the response. We would add one additional rule to this group, that being: the nutrient in question has to follow an appropriate dosing schedule matching the physiological system being investigated. 23 At the initiation of these RCTs, our end points were safety of the dosing, attained circulating level of maternal 25(OH)D, growth parameters of the infant, and bone-mineral-density of the mother and infant. As for the other factors mentioned in the previous section on vitamin D relationships based on observational studies, those associations had not been made at study initiation, and as a result we had no idea to even look for them, let alone propose them as end points. As such, these end points were analyzed as post hoc analyses. When our studies were completed in 2009-2010, we were aware of the observational data suggesting favorable efforts of vitamin D on pregnancy outcomes beyond calcium homeostasis. Of course we had collected all of the data on our patient's outcomes during the trials for safety reasons, and so they were subsequently analyzed. These data were first presented in 2009 at The Vitamin D Workshop in Brugge, Belgium. The data from our studies, when analyzed on an intent-to-treat basis, clearly demonstrated increased vitamin D supplementation decreased complications of pregnancy and C-section births. 30, 113 Further, RCT data and analysis by our group and others have clearly demonstrated that higher doses of vitamin D during pregnancy improve birth outcome data. 104, 113 RCT studies beyond our own have recently demonstrated vitamin D to greatly decrease complications of birth and gestational diabetes, [116] [117] 120 aeroallergen sensitization 119 and markers of regulatory immunity. 121 The most informative of these RCT studies was performed by Sablok et al. , and supplemented the treatment arm with substantial amounts of vitamin D starting at 20 weeks of gestation. The control group received placebo and thus remained profoundly vitamin D deficient throughout pregnancy. Vitamin D treatment in these women resulted in a substantial decline in the complications of pregnancy (Figure 2) . Further, the compliance rate of the women was 100% because the physicians administered the vitamin D to each patient. A study of this type could never be performed in the US as it would be deemed unethical. Be that as it may, it demonstrated the highly significant effect of vitamin D supplementation on the complications of pregnancy. These findings were novel and controversial when they were first presented in 2009 in Belgium.Despite there being high evidence (level 1B) for changing vitamin D dosing and definitions of sufficiency during pregnancy, there was much resistance to change; however, with time and supportive data,these "new" conceptshave prevailed above bias. ) to pregnant women across the three major racial/ethnic groups in the US from 16 weeks of gestation until delivery. The primary endpoint was prevention of asthma/wheeze in the infant/child at 1-3 years post birth. Nearly 900 high-risk subjects were enrolled and completed the study, which recently was published. 99 The results of this study are quite clear: vitamin D supplementation during pregnancy will decrease asthma or recurrent wheezing rates in children (Figure 3) .
A nearly identical RCT study performed in Denmark also recently has been published. 118 The journal in which these articles appeared-JAMA-has attempted to minimize the results and impact of these studies with an Editorial. 124 In response to this negativity, the authors of these two RCTs performed a meta-analysis (H Wolsk, personal communication). Keep in mind, that a meta-analysis of RCTs is the highest form of validation for therapy/prevention/etiology/ harm as defined by The Centre for Evidence-Based Medicine at Oxford University. 125 The results from these RCTs and meta-analysis studies in women with offspring at high risk for asthma are quite clear: vitamin D 3 given to a pregnant woman will prevent asthma/wheeze in her child (H Wolsk, personal communication). 99, 118 The mechanisms by which this occurs remain unknown but it is likely that epigenetic in utero changes triggered by vitamin D administered to the pregnant women impart functional changes in the fetus. [126] [127] [128] Further analysis of the VDAART study published in JAMA 99 reveal some startling findings. Included in that publication "buried" in the supplemental data is the following: Weiss et al have analyzed the data by post hoc stratification by maternal third trimester circulating 25(OH)D levels. In this case, circulating 25(OH)D serves as a biomarker of patient compliance for taking supplemental vitamin D during pregnancy. In the JAMA publication, adherence or compliance was a huge problem that could not be dealt with in the intent-to-treat study analysis. 99 This nonadherence was especially acute in the African-American subjects who comprised 43% of the total study subjects and adhered to the prescribed supplementation regimen-as assessed by pill counts and electronic medical cap monitoring-50% of the time. What was the result from this? This non-adherence could bias the study toward null Top 10 significantly enriched transcription factor networks of the 202 annotated genes from the green module. For each network, the GO processes are shown along with the number of genes from the green network that are enriched within each network and the number of total nodes that define the network. Total nodes = total number of objects in the network (database); seed nodes = number of objects in green data set. Hypergeometric test adjusted for multiple comparisons using Benjamini & Hochberg (Po0.05). Cited from Ref 128, and used with permission from the publisher.
results. While analyses that take into account compliance may have some intrinsic bias as behaviors for taking the study pill could be associated with other behaviors that affect the outcome, nonadherence can significantly affect results of clinical trials, especially in the higher-dose treatment groups where nonadherence can dilute the treatment effect. In these trials, when this bias is factored into the results, the strength of the findings becomes more significant. [98] [99] If one uses circulating 25(OH)D levels as a biomarker of adherence to protocol, the effect of vitamin D preventing childhood asthma becomes highly significant (Po0.02; Figure 4 ). 98, 100 This effect is especially true for the African-American pregnant women in our VDAART study.
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VITAMIN D-INDUCED GENOMIC ALTERATIONS DURING PREGNANCY
If one looks at our original pregnancy study from an intent-to-treat fashion, the results are muddled most likely due to nonadherence; 30 however, taking adherence into account by using circulating 25(OH)D levels as a variable, the true effect on vitamin D supplementation on preterm birth is exposed 104, 114 ( Figures 5 and 6 ). The same associations from our VDAART trial also hold true for the prevention of preeclampsia. 129 How does this occur?
Vitamin D supplementation during pregnancy appears to affect genetic information of several highly functional modules related to systemic inflammation and immune responses and implicates the emergence of a distinctive immune response in women destined to develop preeclampsia. 127, 130 A recent paper by Al-Garawi et al, 128 derived from the VDAART RCT study, provides direct proof of vitamin D's ability to induce genomic changes during pregnancy. Patterns of gene expression during human pregnancy are poorly understood. As mentioned earlier, this study was a RCT of vitamin D supplementation in pregnancy for the reduction of pediatric asthma risk. 94 The trial enrolled 881 women at 10-18 weeks of gestation. Longitudinal gene expression measures were obtained on 30 pregnant women, using RNA isolated from peripheral blood samples obtained in the first and third trimesters. Differentially expressed genes were identified using significance of analysis of microarrays (SAM) and clustered using a weighted gene co-expression network analysis (WGCNA). Gene-set enrichment performed to identify major biological transcriptional profiles between first and third trimesters of pregnancy identified 5 839 significantly differentially expressed genes.Weighted gene co-expression network analysis clustered these transcripts into 14 co-expression modules of which two showed significant correlation with maternal vitamin D levels (Table 1 ). Pathway analysis of these two modules revealed genes enriched in immune defense pathways and extracellular matrix reorganization as well as genes enriched in notch signaling and transcription factor networks ( Data have emerged that demonstrate that vitamin D supplementation during pregnancy alters transcriptome and epigenetic alterations through DNA methylation in genes that regulate metabolic processes, antigen processing, inflammation, regulation of cell death, cell proliferation, transmission of nerve impulse, neurogenesis, neuron differentiation and sensory organ development. 126 For now, what we have are observational studies strongly suggesting vitamin D deficiency during pregnancy as a strong causative agent in the development of MS in later life. 7, 9 Agencies such as the Institute of Medicine and Centers of Disease Control will say that this data must be confirmed by RCT. We state here that such an RCT will NEVER be performed because of the cost involved. How do we know that? A few years ago MS world experts were assembled by the National Multiple Sclerosis Society in Chicago to help design such a study. Following two days of meetings, it was determined that the minimum dollar amount to conduct such an RCT would exceed 50 million dollars and would consume their entire budget for at least 5 years. While the study never went forth and never will, other RCTs of treatment to prevent progression of disease for example, may be conducted. Further, an article by Mokry et al on Mendelian randomization provides strong support of a causal association of vitamin D and lower MS risk in humans. 134 Health providers will have to make decisions on the data that are available that come from corollary studies such as these. An even scarier prospect exists around vitamin D deficiency during pregnancy and neurological disease and altered development. [12] [13] [14] [15] [135] [136] [137] Strong experimental animal evidence points to dire neurological consequences if vitamin D is restricted during pregnancy. 15 If one wants to read the biochemical basis for this we suggest you read recent reviews by Patrick and Ames. [138] [139] They make an excellent case for intrauterine vitamin D deficiency as it relates to autism, attention deficit disorder, bipolar disorder, schizophrenia and impulse behavior all through the control of serotonin synthesis in the neonatal brain. 138 There is also a fair amount of observational data available to support these claims. [12] [13] [14] [15] If that is not convincing we suggest you read a recent prospective, interventional vitamin D trial during pregnancy for the prevention of autism in the newborn. 12 From this data the authors suggest that even performing an RCT would be unethical.
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CURRENT RECOMMENDATION FOR VITAMIN D SUPPLEMENTATION DURING PREGNANCY
At this time, based on RCT data as well as substantial observational and interventional data, we suggest that all pregnant women maintain a circulating 25(OH)D concentration of at least 40 ng · mL − 1 during the earliest time points of pregnancy. 104 This will insure maximum protection from pregnancy complications, including preeclampsia in the mother and asthma formation in the infant. To achieve this, intakes of at least 4 000 IU · d − 1 vitamin D 3 will be required because of variable individual abilities to convert vitamin D to 25(OH)D. 111 These supplements have proven to be safe in thousands of patients over the past 15 years, as not a single adverse event due to supplementation has been observed. Further, this level of supplementation lies within the safe intake level as defined by The Endocrine Society. 22 Finally, does vitamin D qualify as a substance as described by the Barker Hypothesis? The clear answer is yes; it does because its absence during pregnancy imparts detrimental genetic alterations on both mother and fetus.
SUMMARY
At no other time during the lifespan is vitamin D status more important than during pregnancy, affecting not only the mother but also her growing fetus, and later, her growing infant. While there has been considerable controversy surrounding the daily requirement of vitamin D and what constitutes sufficiency during these critical periods, there is mounting evidence of the importance of vitamin D supplementation during pregnancy to achieve a total circulating 25(OH)D concentration of at least 40 ng · mL Past data suggesting that vitamin D is a teratogenic compound is completely unfounded at the physiological doses reviewed in this chapter. As has been shown, significant amounts of vitamin D-whether their source is sunlight or supplement-are required during pregnancy to protect the mother and fetus and impart genomic imprinting on the fetus to ensure long term health.
With enhanced knowledge about vitamin D's role as a preprohormone, it is clear that recommendations about supplementation must mirror what is clinically relevant and evidence-based. Future research that focuses on the critical period(s) leading up to conception and during pregnancy to correct deficiency or maintain optimal vitamin D status remains to be studied. In addition, what effects vitamin D has on genetic signatures that minimize the risk to the mother and developing fetus have not been elucidated. Clearly, while there is much more research that needs to be performed, our understanding of vitamin D requirements during pregnancy has advanced significantly during the past few decades.
